NAD+ and retatrutide — 7 critical facts about the stack.

NAD+ and retatrutide is one of the most discussed research compound combinations in 2026, and for good reason. Retatrutide produces the most aggressive weight loss of any pharmacological compound ever tested — up to 30.3% in the TRIUMPH-1 Phase 3 extension. That speed and scale places significant demands on cellular energy systems, and NAD+ is the molecule sitting at the heart of how cells produce and use that energy.

This guide covers the complete NAD+ and retatrutide picture: why the combination is mechanistically logical, what evidence actually exists, what forms of NAD+ are used in research protocols, what the combination can and cannot be expected to do, and how to source both compounds transparently. General cellular energy information is available through the National Institute on Aging.

NAD+ and Retatrutide — fact 1: what NAD+ actually is

Before understanding the NAD+ and retatrutide combination, understanding what NAD+ is matters. Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in every living cell. It is not a hormone, a receptor agonist, or a signalling molecule in the way that GLP-1 or glucagon are — it is a fundamental molecular workhorse involved in over 500 enzymatic reactions in the human body.

NAD+ is most critical in two contexts relevant to the NAD+ and retatrutide discussion. First, it is the essential cofactor for beta-oxidation — the metabolic process by which cells burn fat for fuel. Without adequate NAD+, the mitochondrial machinery that converts fatty acids into ATP energy cannot function at full capacity. Second, NAD+ activates sirtuins — a family of proteins involved in cellular energy regulation, DNA repair, and metabolic efficiency. NAD+ depletion impairs both processes simultaneously.

NAD+ levels decline with age — by some estimates up to 50% between ages 20 and 60 — and are further depleted by metabolic stress, caloric restriction, and rapid fat mobilisation. This decline is directly relevant to the NAD+ and retatrutide combination, because retatrutide creates precisely the metabolic conditions under which NAD+ demand increases most sharply.

NAD+ and Retatrutide — fact 2: why researchers stack them

The NAD+ and retatrutide combination is driven by a specific concern that emerges from retatrutide’s exceptional efficacy: the faster and more extensively you lose weight, the greater the metabolic demands on cellular energy systems — and the more lean muscle mass you risk losing alongside fat.

Retatrutide’s Phase 3 data showing 30.3% average weight loss at 104 weeks is extraordinary. But it also means people are losing 70-90 lbs over two years in some cases — a rate of loss that would be considered extreme even by bariatric surgery standards. Research consistently shows that the faster weight loss occurs, the higher the proportion of lean mass that is lost alongside fat. The NAD+ and retatrutide stack is primarily an attempt to protect that lean mass by supporting the mitochondrial and cellular energy machinery during the deficit.

Secondary reasons researchers use NAD+ and retatrutide together include managing the fatigue, cognitive fog, and energy dips that some users report during retatrutide dose escalation — symptoms that are plausibly linked to the increased cellular energy demands of rapid metabolic change outpacing the body’s NAD+ availability.

NAD+ and Retatrutide — fact 3: the mechanistic connection

The mechanistic rationale for NAD+ and retatrutide is genuinely compelling — and it’s grounded in retatrutide’s own published data. The Phase 2 liver sub-study showed that retatrutide at 4mg increased beta-hydroxybutyrate (a marker of hepatic fatty acid oxidation) by 93%, and at 12mg by 181%. Beta-hydroxybutyrate is produced when the liver is actively burning fat at high rates — and this fat oxidation process is fundamentally NAD+ dependent.

When retatrutide’s glucagon receptor activation drives the liver to oxidise fat at nearly twice the baseline rate, NAD+ consumption in the relevant enzymatic reactions increases proportionally. If cellular NAD+ levels are already depleted through age or prior metabolic stress, this increased demand may create a bottleneck — the fat is being mobilised, but the machinery to process it is running short of its essential cofactor.

NAD+ and Retatrutide — fact 4: what evidence actually exists

Intellectual honesty requires being clear about what the NAD+ and retatrutide evidence base actually looks like: no human stacking trial has been conducted combining these two compounds. Every protocol in circulation in 2026 is extrapolated from separate bodies of evidence — retatrutide’s Phase 2/3 metabolic data on one side, and NAD+ supplementation research on the other.

The NAD+ evidence that is most directly applicable to the retatrutide context comes from bariatric surgery research, where rapid weight loss similarly increases cellular energy demands. Studies have shown NAD+ depletion following gastric bypass surgery, and some protocols have explored NAD+ supplementation as a supportive intervention. A small 2026 double-blind trial (45 participants, nine arms) found measurable plasma NAD+ increases following IM and IV administration, providing at least proof-of-concept that exogenous NAD+ supplementation achieves meaningful plasma levels.

The separate NAD+ longevity and cellular health literature — covering sirtuin activation, DNA repair, and metabolic efficiency — is extensive and generally robust. The logical extrapolation to the NAD+ and retatrutide context is sound in principle. Whether it produces the lean mass preservation and energy support outcomes that researchers expect requires prospective human data that does not yet exist.

NAD+ and Retatrutide — fact 5: which form of NAD+ to use

The NAD+ and retatrutide research community uses several different NAD+ delivery forms, each with distinct bioavailability profiles. Understanding the options helps in evaluating which is appropriate for different research goals:

• Injectable NAD+ — subcutaneous or intramuscular administration at 50-100mg per dose, 2-3 times per week, achieves the highest plasma concentrations most reliably by bypassing first-pass hepatic metabolism. The 2026 small-scale trial confirmed measurable plasma elevation via IM and SC routes. Injectable protocols are typically used for the active loading phase of NAD+ and retatrutide stacks.
• NMN (Nicotinamide Mononucleotide) — an oral NAD+ precursor that converts to NAD+ in tissues. Typical research doses are 250-500mg daily. Oral bioavailability has improved significantly with enteric-coated and sublingual formulations. NMN is commonly used as the maintenance layer once the injectable loading phase establishes baseline NAD+ levels.
• NR (Nicotinamide Riboside) — another oral precursor, typically dosed at 300-500mg daily. Slightly different metabolic pathway from NMN but similar endpoint. Both NR and NMN are supported by human clinical evidence for increasing NAD+ levels.
• NAD+ IV infusion — highest bioavailability of all delivery routes, used in clinical settings. Less practical for self-administered research protocols but offers the most direct route to rapid NAD+ elevation.

NAD+ and Retatrutide — fact 6: side effects of the combination

NAD+ supplementation has a generally excellent safety profile across the published human literature. The NAD+ and retatrutide combination does not create any documented pharmacological interaction — the two compounds operate through entirely separate pathways. The side effects to be aware of are those of each compound independently.

Injectable NAD+ can cause flushing, warmth, nausea, and a pins-and-needles sensation at higher doses or when administered too rapidly. These effects are dose-dependent and typically resolve within minutes. They are not an allergic reaction — they reflect NAD+’s role in activating vasodilatory pathways at high concentrations. Slowing the injection rate significantly reduces these effects.

The retatrutide side effects — nausea, diarrhoea, constipation, dysesthesia — remain present regardless of NAD+ addition. NAD+ does not reduce or worsen retatrutide’s gastrointestinal side effect profile. The main reason to be alert is that both compounds can independently cause nausea, and if someone is already managing retatrutide GI effects, adding injectable NAD+ during a period of pronounced nausea is worth timing carefully.

NAD+ and Retatrutide — fact 7: research protocol overview

Research protocols combining NAD+ and retatrutide in 2026 follow a fairly consistent structure across the communities discussing this stack:

• Retatrutide — standard weekly subcutaneous injection following the 1mg→2mg→4mg→8mg→12mg monthly escalation schedule. No changes to the retatrutide protocol are made specifically for the stack.
• Injectable NAD+ loading phase — 50-100mg subcutaneous or intramuscular, every other day or 2-3 times per week, typically for the first 4-8 weeks of the retatrutide escalation phase when cellular energy demands are rising most rapidly.
• Oral NAD+ maintenance — NMN 250-500mg daily or NR 300-500mg daily as the ongoing maintenance layer after the injectable loading phase.
• Protein intake emphasis — both for lean mass preservation (directly related to the stack’s primary goal) and to ensure adequate dietary tryptophan, which is a NAD+ biosynthesis precursor.

For the complete retatrutide picture, read our guide on retatrutide phase 3 results explained. Explore our Synedica Retatrutide product page and our NAD+ product page.